{"doi":"10.1002/mc.23919","title":"Targeting FGFR Attenuates Tumor Growth in an Anal Squamous Cell Carcinoma Patient Derived Xenograft Model","abstract":"Anal squamous cell carcinoma (ASCC) is a rare malignancy with a rising incidence and limited treatment options. To identify actionable therapeutic targets, we developed a patient-derived xenograft (PDX) model using a metastatic ASCC sample and performed single-cell RNA sequencing. Our analysis confirmed previously reported genetic mutations highly expressed in the sample, along with copy number alterations, and revealed epithelial cancer cell heterogeneity. Notably, epithelial cells exhibited a low hybrid epithelial-mesenchymal transition (hEMT) signature compared to stromal cells. Among epithelial subpopulations, the most abundant cluster displayed high expression of FGFR1-2 and FGF ligands. Treatment with AZD4547, an FGFR1-3 inhibitor, resulted in a significant reduction in tumor volume over time (p = 0.0036). Immunohistochemistry staining for proliferative Ki67 and cleaved caspase 3 suggested ongoing proliferation in residual cells. Fourier-transform infrared (FTIR) spectroscopy of post-treatment residual tumors revealed significant differences in the Amide I and Amide II regions between AZD4547-treated and control groups. These findings demonstrate that FGFR inhibition effectively attenuates ASCC tumor growth and highlights the promise of precision medicine in managing this rare cancer.","journal":"Molecular Carcinogenesis","year":2025,"id":528138,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.947,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1406162,"name":"Athena Golfinos-Owens","orcid":null,"position":1,"is_corresponding":false},{"id":1405530,"name":"Naren Raja","orcid":"0000-0001-6321-1671","position":2,"is_corresponding":false},{"id":992523,"name":"Levi Arnold","orcid":"0000-0003-4076-5772","position":3,"is_corresponding":false},{"id":1184836,"name":"Pachiappan Arjunan","orcid":"0000-0001-9470-1171","position":4,"is_corresponding":false},{"id":992918,"name":"John Ashcraft","orcid":null,"position":5,"is_corresponding":false},{"id":271053,"name":"Benjamin Martin","orcid":"0000-0001-6510-6824","position":6,"is_corresponding":false},{"id":283967,"name":"Shrikant Anant","orcid":"0000-0003-4193-3053","position":7,"is_corresponding":false},{"id":284304,"name":"Sumedha Gunewardena","orcid":"0000-0003-2097-135X","position":8,"is_corresponding":false},{"id":712003,"name":"Rong Wang","orcid":"0000-0002-1607-8094","position":9,"is_corresponding":false},{"id":271171,"name":"Huy Q. Dinh","orcid":"0000-0002-3307-1126","position":10,"is_corresponding":false},{"id":299503,"name":"Sufi M. Thomas","orcid":"0000-0001-5370-0842","position":11,"is_corresponding":false},{"id":509812,"name":"Thuc Ly","orcid":"0000-0002-3971-5404","position":0,"is_corresponding":true}],"reference_count":57,"raw_metadata":null,"created_at":"2026-07-19T02:50:44.062153Z","pmid":"40256931","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}